Luparp: 177Lu-Psma-617 And Parp Inhibitor Combination For Prostate Cancer

LuPARP: 177Lu-PSMA-617 and PARP inhibitor combination for prostate cancer

The benefits of 177Lu-PSMA-617 plus olaparib for prostate cancer

PRINCE: 177Lu-PSMA-617 and pembrolizumab in prostate cancer

Choosing the correct PARP inhibitor for prostate cancer

Future studies for the combination of 177Lu-PSMA-617 and olaparib

Predicting 177Lu-PSMA-617 in men with prostate cancer with nomograms

177Lu-PSMA-617 for the early treatment of prostate cancer

177Lu-PSMA-617 for prostate cancer: TheraP, VISION, UpFrontPSMA and LuTectomy

Assessing PARP inhibition and BRCA1/2 as a prognostic biomarker in mCRPC

Combining a PARP and PD-L1 inhibitor to treat prostate cancer

Phase I/II Trial of 177Lu−J591 and 177Lu−PSMA−617 in mCRCP

Role of PARP Inhibitors in Prostate Cancer

Grand Rounds in Urology

PSMAfore Trial & Enzalutamide with 177Lu-PSMA-617 for mCRPC | Dr. Dharmender Malik | 05th Knowledge

CRSF - Cancer Research and Statistic Foundation

Dr. Morgan on Combinations With PARP Inhibitors in Prostate Cancer

PARP inhibitors for metastatic hormone sensitive prostate cancer

PARP Inhibitor Combinations and Future of Ovarian Cancer

Targeted Oncology

TheraP trial

European Association of Urology

Rucaparib and Olaparib: Two New Treatments Approved for Advanced Prostate Cancer | PCRI

Prostate Cancer Research Institute

2020 In Review: Olaparib & Rucaparib, FDA Approval | Ask a Prostate Expert, Mark Scholz, MD

Prostate Cancer Research Institute

UpFrontPSMA trial: 177Lu-PSMA-617 and docetaxel in mHNPC